Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

InSilico Medicine

InSilico Medicine?uq=K9LEA9hy
2014 FOUNDED
PRIVATE STATUS
41-50 EMPLOYEES
Series A LATEST DEAL TYPE
$6M LATEST DEAL AMOUNT
8 INVESTORS
Description

Developer of a comprehensive drug discovery engine created to extend healthy longevity through innovative AI solution for drug discovery and aging research. The company uses deep learning technology for drug discovery and drug re-purposing for aging and age-related diseases. It provides services to large pharmaceutical, nutrition, regenerative medicine and personalized medicine companies, as well as to academic institutions and non-profit organizations, allowing for the identification of molecules that may be effective against a variety of cancers as well as metabolic, cardiovascular and central nervous system diseases.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • Johns Hopkins University 9601 Medical Center Drive
  • Suite 127
  • Rockville, MD 20850
  • United States

+1 (443) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore InSilico Medicine’s full profile, request a free trial.

InSilico Medicine Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 18-Jun-2018 $6M 000.00 0000 Completed Generating Revenue
3. Early Stage VC 18-Jul-2017 000.00 000.00 Completed Generating Revenue
2. Convertible Debt 01-Nov-2015 $800K $1.5M Completed Startup
1. Seed Round 16-Apr-2014 $700K $700K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

InSilico Medicine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 000,000 00.000000 00.00 00.00 00 00.00 000
To view this company’s complete Cap Table, request access »

InSilico Medicine Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000.00 19-Jul-2018 00000 0000000 Other Healthcare Technology Systems 000000000 00000000000 00.0
To view this company’s complete investment and acquisition history, request access »

InSilico Medicine Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bold Capital Partners Venture Capital Minority 000 0000 000000 0
Juvenescence VC-Backed Company Minority 000 0000 000000 0
Mann Bioinvest Venture Capital Minority 000 0000 000000 0
Pavilion Capital PE/Buyout Minority 000 0000 000000 0
SoGal Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

InSilico Medicine Executive Team (3)

Name Title Board
Seat
Contact
Info
Alexander Zhavoronkov Ph.D Co-Founder, Chief Executive Officer & Board Member
Alexander Aliper President, EMEA
Qingsong Zhu Ph.D Chief Operating Officer & Secretary

InSilico Medicine Board Members (2)

Name Representing Role Since Contact
Info
Alexander Zhavoronkov Ph.D InSilico Medicine Co-Founder, Chief Executive Officer & Board Member 000 0000
James Mellon Juvenescence Board Member 000 0000